Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tepotinib Hydrochloride

FDA-approved product (tablet, oral), marketed as Tepmetko.

Registered studies
6
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Tepotinib Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

6registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tepotinib Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tepotinib Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

    NCT06908993 · start 2025-12-09

    Registered record
    Registry ID
    NCT06908993
    Conditions
    Advanced Non Small Cell Lung Cancer; MET Exon 14 Mutation
    Interventions
    Tepotinib; Pemetrexed (Alimta); Vinorelbine; Gemcitabine alone; Docetaxel; Paclitaxel; Pembrolizumab; Nivolumab; Atezolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-12-09
    Completion
    2028-07-15
    Enrolment
    133

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non Small Cell Lung Cancer; MET Exon 14 Mutation
    InterventionTepotinib; Pemetrexed (Alimta); Vinorelbine; Gemcitabine alone +5 more
    PhasePhase 3
    Registry statusRecruiting

  • POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC

    NCT05782361 · start 2023-05-03

    Registered record
    Registry ID
    NCT05782361
    Conditions
    Advanced Cancer; Non Small Cell Lung Cancer
    Interventions
    Tepotinib; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2023-05-03
    Completion
    2029-01-09
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer; Non Small Cell Lung Cancer
    InterventionTepotinib; Pembrolizumab
    PhasePhase 1
    Registry statusActive not recruiting

  • Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants

    NCT05203822 · start 2022-01-21

    Registered record
    Registry ID
    NCT05203822
    Conditions
    Healthy
    Interventions
    Tepotinib (HydroChloride hydrate); Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-01-21
    Completion
    2022-07-05
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTepotinib (HydroChloride hydrate); Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants

    NCT05213481 · start 2021-12-15

    Registered record
    Registry ID
    NCT05213481
    Conditions
    Healthy
    Interventions
    Tepotinib; Carbamazepine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-12-15
    Completion
    2022-05-06
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTepotinib; Carbamazepine
    PhasePhase 1
    Registry statusCompleted

  • The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

    NCT04591431 · start 2020-10-07

    Registered record
    Registry ID
    NCT04591431
    Conditions
    Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    Interventions
    Erlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab; Lapatinib; Everolimus; Vemurafenib; Cobimetinib; Alectinib; Brigatinib; Palbociclib; Ponatinib; Vismogedib; Itacitinib; Ipatasertib; Entrectinib; Atezolizumab; Nivolumab; Ipilimumab; Pemigatinib; Oncology Drugs; Pralsetinib; Selpercatinib; Talazoparib; Tepotinib; Alpelisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-10-07
    Completion
    2025-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer
    InterventionErlotinib; Trastuzumab; Trastuzumab emtansine; Pertuzumab +22 more
    PhasePhase 2
    Registry statusUnknown

  • The Drug Rediscovery Protocol (DRUP Trial)

    NCT02925234 · start 2016-08

    Registered record
    Registry ID
    NCT02925234
    Conditions
    Cancer; Tumors; Neoplasm; Neoplasia
    Interventions
    Panitumumab; Olaparib; Dabrafenib; Nilotinib; Trametinib; Erlotinib; Trastuzumab and Pertuzumab (combination treatment); Vemurafenib and Cobimetinib (combination treatment); Vismodegib; Regorafenib; Nivolumab; Afatinib; Dabrafenib and trametinib; Ribociclib; Lenvatinib; Pembrolizumab; Durvalumab; Rucaparib; Axitinib; Palbociclib; Crizotinib; Sunitinib; Cabozantinib; Abemaciclib; Alectinib; Atezolizumab and Bevacizumab; Ipilimumab and nivolumab; Entrectinib; Talazoparib; Dacomitinib; Lorlatinib; Erdafitinib; Alpelisib; Niraparib; Pemigatinib; Selpercatinib; Tepotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2016-08
    Completion
    2027-12
    Enrolment
    1,550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Tumors; Neoplasm; Neoplasia
    InterventionPanitumumab; Olaparib; Dabrafenib; Nilotinib +33 more
    PhasePhase 2
    Registry statusRecruiting